Always Remember - Buy The Dip

Sentiment Analysis For TBIO

The news is currently generally neutral for TBIO.

Based on TextBlob analysis of Yahoo! Finance news summaries for TBIO on 2015-04-30.

Yahoo! Finance News for TBIO

Earnings Reported After The Bell Apr. 15
Earnings Reported After The Bell Apr. 15

Health Care Sector Update for 03/18/2015: TBIO,NVGN,NKTR
Top Health Care Stocks JNJ +1.38% PZE +0.32% MRK +0.53% ABT +1.97% AMGN +1.96% Health care stocks were broadly higher this afternoon with the NYSE Health Care Sector Index climbing 1.7% while shares of health care companies in the

U.S. Stocks End Mostly Lower; Nasdaq Gains
U.S. Stocks End Mostly Lower; Nasdaq Gains

DGX' New Genetic Test for Opioid Cure - Analyst Blog
Recently, Quest Diagnostics ( DGX ) introduced its latest lab developed genetic test for the delivery of personalized opioid pain relieving treatment. Quest Diagnostics developed this test using Transgenomic, Inc. 's ( TBIO ) gene variant through

Q1 Revenue In-Line. Amgen Deal Is Encouraging - Analyst Blog
By Brian Marckx, CFA Q1 2013 RESULTS: Revenue In-Line, EPS Miss on Higher SG&A. Amgen Deal is Encouraging Transgenomic (OTC: TBIO ) reported financial results for Q1 ending March 31, 2013 on May 8th. Revenue was up 2% yoy and dead-on with our $7.4 million estimate. While Laboratory Services

TBIO: Look For Resurgence In 2013 - Analyst Blog
TBIO: Look For Resurgence In 2013 By Brian Marckx, CFA Q4 2012 RESULTS Transgenomic (OTC: TBIO ) reported financial results for Q4 ending December 31, 2012 on March 13th. Revenue was down 15% yoy and far below our estimate due to relative weakness in Clinical Lab and the Diagnostics Instruments

ScoliScore/C-GAAP Should Drive Clinical Lab Revs in 2013 - Analyst Blog
ScoliScore/C-GAAP Should Drive Clinical Lab Revs in 2013 By Brian Marckx, CFA Q3 2012 RESULTS Transgenomic ( TBIO ) reported financial results for Q3 ending September 30, 2012 on November 8th. Revenue fell just over 4% yoy and was well below our estimate due to relatively disappointing numbers

ScoliScore Could Be A Needle-Mover For TBIO - Analyst Blog
ScoliScore Could Be A Needle-Mover For TBIO ScoliScore Could Be A Needle-Mover For TBIO Yesterday (8/28/2012) Transgenomic ( TBIO ) announced an agreement to acquire ScoliScore, a saliva-based genetic test to determine the likelihood that a mild curvature in the spine of adolescents will progress to one

coliScore Could Be A Needle-Mover For TBIO - Analyst Blog
coliScore Could Be A Needle-Mover For TBIO Brian Marckx, CFA Yesterday (8/28/2012) Transgenomic ( TBIO ) announced an agreement to acquire ScoliScore, a saliva-based genetic test to determine the likelihood that a mild curvature in the spine of adolescents will progress to one which eventually requires

TBIO: Good Q2. Future Shaping Up Nicely - Analyst Blog
TBIO: Good Q2. Future Shaping Up Nicely Brian Marckx, CFA Q2 2012 RESULTS Transgenomic Inc. ( TBIO ) reported financial results for Q2 ending June 30, 2012 on August 1st. Revenue was up almost 19% and set an all-time quarterly record. Very strong sales from clinical lab partially due to the reversal

Milestone Hit With ICE COLD-PCR Launch - Analyst Blog
Milestone Hit With ICE COLD-PCR Launch Brian Marckx, CFA This morning Transgenomic Inc. ( TBIO ) announced a significant milestone with the launch of their ICE COLD-PCR technology at ASCO 2012 (American Society of Clinical Oncology meeting). ICE COLD-PCR affords very high sensitivity and enables sampling

Software Blip Causes Slight Revenue Miss - Analyst Blog
Software Blip Causes Slight Revenue Miss Brian Marckx, CFA Q1 2012 RESULTS Transgenomic Inc. ( TBIO ) reported financial results for Q1 ending March 31, 2012 on May 8th.  Revenue missed our number by about 6%.  The majority of the miss